ELISA/assay

KRIBIOLISA™ Pembrolizumab (KEYTRUDA) ELISA

KBI1084

1 x 96 wells

940 USD

KRIBIOLISA™ Pembrolizumab (KEYTRUDA) ELISA

ELISA

1 x 96 wells

940 USD

Sensitivity: 50ng/ml Sample Type: Serum, Plasma Calibrator Range: 0-1000ng/ml Enzyme Immunoassay for quantitative detection of Pembrolizumab in serum and plasma. Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is a therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body's own tissues; it is a so-called immune checkpoint. Many cancers make proteins that bind to PD-1, thus shutting down the ability of the body to kill the cancer on its own. Inhibiting PD1 on the lymphocytes prevents this, allowing the immune system to target and destroy cancer cells. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year

Human

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and cervical cancer. Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). It is on the World Health Organization's List of Essential Medicines.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

0 ng/ml - 640 ng/ml

8.25 ng/ml

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Pembrolizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Pembrolizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-pembrolizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Pembrolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Pembrolizumab

RUO

2-8 degrees C